작성자 Chas   조회Hit 5   작성일2024-04-11

Nase-3beta activation. FEBS Lett 2005, 579:6230?236. 11. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA: Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 2005, 11:164?69. 12. Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT: Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006, 168:1598?607. 13. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312?18. 14. Gonzalez-Scarano F, Baltuch G: Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999, 22:219?40. 15. Thomas WE: Brain macrophages: evaluation of microglia and their functions. Brain Res Brain Res Rev 1992, 17:61?4. 16. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/21715270 Aloisi F: Immune function of microglia. Glia 2001, 36:165?79.Two to three different areas surrounding the site of injection from five slices from each mouse were defined for the analysis of activated microglial cells and cells containing hypersphosphorylated tau and NFTs. Statistical analysis was performed using 2-way-ANOVAs followed by Tukey multiple comparison tests. A significance level of p 0.05 was set for all statistical tests.Competing interests The authors declare that they have no competing interests. Authors' contributions MG participated in the design of the study, conducted the experiments, analyzed the data, and wrote the manuscript. HS participated in the design of the study, synthesized the bioactive nanoparticles and helped to draft theGlat et al. Journal of Nanobiotechnology 2013, 11:32 http://www.jnanobiotechnology.com/content/11/1/Page PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/3081428 12 of17. Hanisch UK: Microglia as a source and target of cytokines. Glia 2002, 40:140?55. 18. Cullheim S, Thams S: The microglial networks of the brain and their role in neuronal network plasticity after lesion. Brain Res Rev 2007, 55:89?6. 19. Trapp BD, Wujek JR, Criste GA, Jalabi W, Yin X, Kidd GJ, Stohlman S, Ransohoff R: Evidence for synaptic stripping by cortical 4,4,5,5-Tetramethyl-2-(2-methylprop-1-en-1-yl)-1,3,2-dioxaborolane microglia. Glia 2007, 55:360?68. 20. Neumann H, Kotter MR, Franklin RJ: Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009, 132:288?95. 21. Streit WJ, Braak H, Xue QS, Bechmann I: Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009, 118:475?85. 22. Li [2-(3-Methyl-1,2,4-oxadiazol-5-yl)ethyl]amine hydrochloride L, Lu J, Tay SS, Moochhala SM, He BP: The function of microglia, either neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro. Brain Res 2007, 1159:8?7. 23. Nakajima K, Honda S, Tohyama Y, Imai Y, Kohsaka S, Kurihara T: Neurotrophin secretion from cultured microglia. J Neurosci Res 2001, 65:322?31. 24. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337?51. 25. Gorlovoy P, Larionov S, Pham TT, Neumann H: Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J 2009, 23:2502?513. 26. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM: Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005, 25:8843?853. 27. Ugaro.